Diagnostic and prognostic significance of CA IX and suPAR in gastric cancer
This study was intended to evaluate the prognostic and diagnostic significance of carbonic anhydrase IX (CA IX) and soluble urokinase plasminogen activator receptor (suPAR) levels in gastric cancer patients. CA IX and suPAR were analyzed from serum and plasma samples of gastric cancer patients. Fift...
Gespeichert in:
| Veröffentlicht in: | Medical oncology (Northwood, London, England) London, England), 2013-06, Vol.30 (2), p.540-540, Article 540 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 540 |
|---|---|
| container_issue | 2 |
| container_start_page | 540 |
| container_title | Medical oncology (Northwood, London, England) |
| container_volume | 30 |
| creator | Fidan, Evren Mentese, Ahmet Ozdemir, Feyyaz Deger, Orhan Kavgaci, Halil Caner Karahan, S. Aydin, Fazil |
| description | This study was intended to evaluate the prognostic and diagnostic significance of carbonic anhydrase IX (CA IX) and soluble urokinase plasminogen activator receptor (suPAR) levels in gastric cancer patients. CA IX and suPAR were analyzed from serum and plasma samples of gastric cancer patients. Fifty patients and 34 controls were enrolled. CA IX and suPAR levels were statistically significantly higher in the patient group (patient; 182.5 ± 212.4, control; 47.3 ± 32,
P
= 0.0001 and patient; 5.74 ± 5.3, control; 2.27 ± 0.77,
P
= 0.0001, respectively). CA IX and suPAR levels were higher in metastatic subjects (metastatic; 227.1 ± 273.5, non-metastatic; 147.4 ± 144.1,
P
> 0.05). Prognosis was worse in the patient group with elevated suPAR. CA IX and especially suPAR are correlated with the presence and stage of the disease. High suPAR levels indicate a poorer prognosis in gastric cancer patients. |
| doi_str_mv | 10.1007/s12032-013-0540-9 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1318698018</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1318698018</sourcerecordid><originalsourceid>FETCH-LOGICAL-c438t-397d1585dbf0c217406d7c3b1cf85beb2605d90c347c021e1827ad293713b3223</originalsourceid><addsrcrecordid>eNp1kE9LAzEQxYMotlY_gBdZ8OJlNZNsNsmx1L9YUESht7CbzZaUNluT3YPf3rTbigieMmF-8-bNQ-gc8DVgzG8CEExJioGmmGU4lQdoCIzJFCjMDmNNGY-dHA_QSQgLjAkwIo_RgFAGJCNiiJ5vbTF3TWitTgpXJWvf7L_Bzp2trS6cNklTJ5Nx8jTbQqF7Hb8l1iXzIrQ-olvGn6KjulgGc7Z7R-jj_u598phOXx6eJuNpqjMq2pRKXgETrCprrAnwDOcV17QEXQtWmpLkmFUSa5pxHR0bEIQXFZGUAy0pIXSErnrdaPazM6FVKxu0WS4LZ5ouqHi9yKXAICJ6-QddNJ130V2kWJ5lG_FIQU9p34TgTa3W3q4K_6UAq03Sqk9axaTVJmkl48zFTrkrV6b6mdhHGwHSAyG23Nz4X6v_Vf0GB-WFkw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1356441827</pqid></control><display><type>article</type><title>Diagnostic and prognostic significance of CA IX and suPAR in gastric cancer</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>Fidan, Evren ; Mentese, Ahmet ; Ozdemir, Feyyaz ; Deger, Orhan ; Kavgaci, Halil ; Caner Karahan, S. ; Aydin, Fazil</creator><creatorcontrib>Fidan, Evren ; Mentese, Ahmet ; Ozdemir, Feyyaz ; Deger, Orhan ; Kavgaci, Halil ; Caner Karahan, S. ; Aydin, Fazil</creatorcontrib><description>This study was intended to evaluate the prognostic and diagnostic significance of carbonic anhydrase IX (CA IX) and soluble urokinase plasminogen activator receptor (suPAR) levels in gastric cancer patients. CA IX and suPAR were analyzed from serum and plasma samples of gastric cancer patients. Fifty patients and 34 controls were enrolled. CA IX and suPAR levels were statistically significantly higher in the patient group (patient; 182.5 ± 212.4, control; 47.3 ± 32,
P
= 0.0001 and patient; 5.74 ± 5.3, control; 2.27 ± 0.77,
P
= 0.0001, respectively). CA IX and suPAR levels were higher in metastatic subjects (metastatic; 227.1 ± 273.5, non-metastatic; 147.4 ± 144.1,
P
> 0.05). Prognosis was worse in the patient group with elevated suPAR. CA IX and especially suPAR are correlated with the presence and stage of the disease. High suPAR levels indicate a poorer prognosis in gastric cancer patients.</description><identifier>ISSN: 1357-0560</identifier><identifier>EISSN: 1559-131X</identifier><identifier>DOI: 10.1007/s12032-013-0540-9</identifier><identifier>PMID: 23512428</identifier><identifier>CODEN: MONCEZ</identifier><language>eng</language><publisher>Boston: Springer US</publisher><subject>Adult ; Aged ; Antigens, Neoplasm - biosynthesis ; Antigens, Neoplasm - blood ; Biomarkers, Tumor - biosynthesis ; Biomarkers, Tumor - blood ; Carbonic Anhydrase IX ; Carbonic Anhydrases - biosynthesis ; Carbonic Anhydrases - blood ; Case-Control Studies ; Female ; Hematology ; Humans ; Internal Medicine ; Male ; Medicine ; Medicine & Public Health ; Middle Aged ; Oncology ; Original Paper ; Pathology ; Prognosis ; Receptors, Urokinase Plasminogen Activator - biosynthesis ; Receptors, Urokinase Plasminogen Activator - blood ; Stomach Neoplasms - blood ; Stomach Neoplasms - diagnosis ; Stomach Neoplasms - mortality ; Survival Rate - trends ; Up-Regulation - genetics</subject><ispartof>Medical oncology (Northwood, London, England), 2013-06, Vol.30 (2), p.540-540, Article 540</ispartof><rights>Springer Science+Business Media New York 2013</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c438t-397d1585dbf0c217406d7c3b1cf85beb2605d90c347c021e1827ad293713b3223</citedby><cites>FETCH-LOGICAL-c438t-397d1585dbf0c217406d7c3b1cf85beb2605d90c347c021e1827ad293713b3223</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s12032-013-0540-9$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s12032-013-0540-9$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23512428$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Fidan, Evren</creatorcontrib><creatorcontrib>Mentese, Ahmet</creatorcontrib><creatorcontrib>Ozdemir, Feyyaz</creatorcontrib><creatorcontrib>Deger, Orhan</creatorcontrib><creatorcontrib>Kavgaci, Halil</creatorcontrib><creatorcontrib>Caner Karahan, S.</creatorcontrib><creatorcontrib>Aydin, Fazil</creatorcontrib><title>Diagnostic and prognostic significance of CA IX and suPAR in gastric cancer</title><title>Medical oncology (Northwood, London, England)</title><addtitle>Med Oncol</addtitle><addtitle>Med Oncol</addtitle><description>This study was intended to evaluate the prognostic and diagnostic significance of carbonic anhydrase IX (CA IX) and soluble urokinase plasminogen activator receptor (suPAR) levels in gastric cancer patients. CA IX and suPAR were analyzed from serum and plasma samples of gastric cancer patients. Fifty patients and 34 controls were enrolled. CA IX and suPAR levels were statistically significantly higher in the patient group (patient; 182.5 ± 212.4, control; 47.3 ± 32,
P
= 0.0001 and patient; 5.74 ± 5.3, control; 2.27 ± 0.77,
P
= 0.0001, respectively). CA IX and suPAR levels were higher in metastatic subjects (metastatic; 227.1 ± 273.5, non-metastatic; 147.4 ± 144.1,
P
> 0.05). Prognosis was worse in the patient group with elevated suPAR. CA IX and especially suPAR are correlated with the presence and stage of the disease. High suPAR levels indicate a poorer prognosis in gastric cancer patients.</description><subject>Adult</subject><subject>Aged</subject><subject>Antigens, Neoplasm - biosynthesis</subject><subject>Antigens, Neoplasm - blood</subject><subject>Biomarkers, Tumor - biosynthesis</subject><subject>Biomarkers, Tumor - blood</subject><subject>Carbonic Anhydrase IX</subject><subject>Carbonic Anhydrases - biosynthesis</subject><subject>Carbonic Anhydrases - blood</subject><subject>Case-Control Studies</subject><subject>Female</subject><subject>Hematology</subject><subject>Humans</subject><subject>Internal Medicine</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Oncology</subject><subject>Original Paper</subject><subject>Pathology</subject><subject>Prognosis</subject><subject>Receptors, Urokinase Plasminogen Activator - biosynthesis</subject><subject>Receptors, Urokinase Plasminogen Activator - blood</subject><subject>Stomach Neoplasms - blood</subject><subject>Stomach Neoplasms - diagnosis</subject><subject>Stomach Neoplasms - mortality</subject><subject>Survival Rate - trends</subject><subject>Up-Regulation - genetics</subject><issn>1357-0560</issn><issn>1559-131X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp1kE9LAzEQxYMotlY_gBdZ8OJlNZNsNsmx1L9YUESht7CbzZaUNluT3YPf3rTbigieMmF-8-bNQ-gc8DVgzG8CEExJioGmmGU4lQdoCIzJFCjMDmNNGY-dHA_QSQgLjAkwIo_RgFAGJCNiiJ5vbTF3TWitTgpXJWvf7L_Bzp2trS6cNklTJ5Nx8jTbQqF7Hb8l1iXzIrQ-olvGn6KjulgGc7Z7R-jj_u598phOXx6eJuNpqjMq2pRKXgETrCprrAnwDOcV17QEXQtWmpLkmFUSa5pxHR0bEIQXFZGUAy0pIXSErnrdaPazM6FVKxu0WS4LZ5ouqHi9yKXAICJ6-QddNJ130V2kWJ5lG_FIQU9p34TgTa3W3q4K_6UAq03Sqk9axaTVJmkl48zFTrkrV6b6mdhHGwHSAyG23Nz4X6v_Vf0GB-WFkw</recordid><startdate>20130601</startdate><enddate>20130601</enddate><creator>Fidan, Evren</creator><creator>Mentese, Ahmet</creator><creator>Ozdemir, Feyyaz</creator><creator>Deger, Orhan</creator><creator>Kavgaci, Halil</creator><creator>Caner Karahan, S.</creator><creator>Aydin, Fazil</creator><general>Springer US</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope></search><sort><creationdate>20130601</creationdate><title>Diagnostic and prognostic significance of CA IX and suPAR in gastric cancer</title><author>Fidan, Evren ; Mentese, Ahmet ; Ozdemir, Feyyaz ; Deger, Orhan ; Kavgaci, Halil ; Caner Karahan, S. ; Aydin, Fazil</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c438t-397d1585dbf0c217406d7c3b1cf85beb2605d90c347c021e1827ad293713b3223</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antigens, Neoplasm - biosynthesis</topic><topic>Antigens, Neoplasm - blood</topic><topic>Biomarkers, Tumor - biosynthesis</topic><topic>Biomarkers, Tumor - blood</topic><topic>Carbonic Anhydrase IX</topic><topic>Carbonic Anhydrases - biosynthesis</topic><topic>Carbonic Anhydrases - blood</topic><topic>Case-Control Studies</topic><topic>Female</topic><topic>Hematology</topic><topic>Humans</topic><topic>Internal Medicine</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Oncology</topic><topic>Original Paper</topic><topic>Pathology</topic><topic>Prognosis</topic><topic>Receptors, Urokinase Plasminogen Activator - biosynthesis</topic><topic>Receptors, Urokinase Plasminogen Activator - blood</topic><topic>Stomach Neoplasms - blood</topic><topic>Stomach Neoplasms - diagnosis</topic><topic>Stomach Neoplasms - mortality</topic><topic>Survival Rate - trends</topic><topic>Up-Regulation - genetics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fidan, Evren</creatorcontrib><creatorcontrib>Mentese, Ahmet</creatorcontrib><creatorcontrib>Ozdemir, Feyyaz</creatorcontrib><creatorcontrib>Deger, Orhan</creatorcontrib><creatorcontrib>Kavgaci, Halil</creatorcontrib><creatorcontrib>Caner Karahan, S.</creatorcontrib><creatorcontrib>Aydin, Fazil</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><jtitle>Medical oncology (Northwood, London, England)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fidan, Evren</au><au>Mentese, Ahmet</au><au>Ozdemir, Feyyaz</au><au>Deger, Orhan</au><au>Kavgaci, Halil</au><au>Caner Karahan, S.</au><au>Aydin, Fazil</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Diagnostic and prognostic significance of CA IX and suPAR in gastric cancer</atitle><jtitle>Medical oncology (Northwood, London, England)</jtitle><stitle>Med Oncol</stitle><addtitle>Med Oncol</addtitle><date>2013-06-01</date><risdate>2013</risdate><volume>30</volume><issue>2</issue><spage>540</spage><epage>540</epage><pages>540-540</pages><artnum>540</artnum><issn>1357-0560</issn><eissn>1559-131X</eissn><coden>MONCEZ</coden><abstract>This study was intended to evaluate the prognostic and diagnostic significance of carbonic anhydrase IX (CA IX) and soluble urokinase plasminogen activator receptor (suPAR) levels in gastric cancer patients. CA IX and suPAR were analyzed from serum and plasma samples of gastric cancer patients. Fifty patients and 34 controls were enrolled. CA IX and suPAR levels were statistically significantly higher in the patient group (patient; 182.5 ± 212.4, control; 47.3 ± 32,
P
= 0.0001 and patient; 5.74 ± 5.3, control; 2.27 ± 0.77,
P
= 0.0001, respectively). CA IX and suPAR levels were higher in metastatic subjects (metastatic; 227.1 ± 273.5, non-metastatic; 147.4 ± 144.1,
P
> 0.05). Prognosis was worse in the patient group with elevated suPAR. CA IX and especially suPAR are correlated with the presence and stage of the disease. High suPAR levels indicate a poorer prognosis in gastric cancer patients.</abstract><cop>Boston</cop><pub>Springer US</pub><pmid>23512428</pmid><doi>10.1007/s12032-013-0540-9</doi><tpages>1</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1357-0560 |
| ispartof | Medical oncology (Northwood, London, England), 2013-06, Vol.30 (2), p.540-540, Article 540 |
| issn | 1357-0560 1559-131X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1318698018 |
| source | MEDLINE; SpringerLink Journals |
| subjects | Adult Aged Antigens, Neoplasm - biosynthesis Antigens, Neoplasm - blood Biomarkers, Tumor - biosynthesis Biomarkers, Tumor - blood Carbonic Anhydrase IX Carbonic Anhydrases - biosynthesis Carbonic Anhydrases - blood Case-Control Studies Female Hematology Humans Internal Medicine Male Medicine Medicine & Public Health Middle Aged Oncology Original Paper Pathology Prognosis Receptors, Urokinase Plasminogen Activator - biosynthesis Receptors, Urokinase Plasminogen Activator - blood Stomach Neoplasms - blood Stomach Neoplasms - diagnosis Stomach Neoplasms - mortality Survival Rate - trends Up-Regulation - genetics |
| title | Diagnostic and prognostic significance of CA IX and suPAR in gastric cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T09%3A30%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Diagnostic%20and%20prognostic%20significance%20of%20CA%20IX%20and%20suPAR%20in%20gastric%20cancer&rft.jtitle=Medical%20oncology%20(Northwood,%20London,%20England)&rft.au=Fidan,%20Evren&rft.date=2013-06-01&rft.volume=30&rft.issue=2&rft.spage=540&rft.epage=540&rft.pages=540-540&rft.artnum=540&rft.issn=1357-0560&rft.eissn=1559-131X&rft.coden=MONCEZ&rft_id=info:doi/10.1007/s12032-013-0540-9&rft_dat=%3Cproquest_cross%3E1318698018%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1356441827&rft_id=info:pmid/23512428&rfr_iscdi=true |